SCHEMBL23999972

SCHEMBL23999972

CC(=O)Nc1ccc(-c2nc3nc(Cl)ccc3[nH]2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 5/20 0.60
HPGD P15428 4/20 0.60
TP53 P04637 4/20 0.60
HSD17B10 Q99714 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
PRMT5 O14744 3/20 0.53
MAPT P10636 1/20 0.53
HPSE Q9Y251 4/20 0.51
DHODH Q02127 2/20 0.51
PARP1 P09874 1/20 0.51
GAA P10253 1/20 0.49
POLB P06746 2/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6258154 0.79 HPSE (0.81) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL23999971 0.78 ALDH1A1 (0.55) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL13405889 0.78 KDM4E (0.81) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL27202537 0.75 ALDH1A1 (1.00) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL20982455 0.75 ALDH1A1 (0.67) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL6477468 0.74 PRMT5 (0.59) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2244714 0.74 HPSE (0.79) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL20982497 0.74 ALDH1A1 (0.66) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL27202458 0.74 HPSE (0.67) KDM4EALDH1A1HPGDTP53HSD17B10
SCHEMBL4403289 0.73 NPC1 (0.71) KDM4EALDH1A1HPGDTP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDM4E 3961/4885ALDH1A1 4544/4885HPGD 2437/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDM4E 4095/4885ALDH1A1 4541/4885HPGD 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.